<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="http://www.fda.gov/oc/datacouncil/stylesheets/spl/spl.xsl" type="text/xsl"?><document xmlns="urn:hl7-org:v3" xmlns:voc="http://www.hl7.org/v3/voc" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 http://www.fda.gov/oc/datacouncil/schemas/spl/spl.xsd">
<id root="fbf43afb-b192-44bd-89d4-10172fea17a5" />
<code code="34391-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="HUMAN PRESCRIPTION DRUG LABELING" />
<title ID="INV-53b04ddc-e90f-4c23-88a8-89e05c226046" mediaType="text/x-hl7-title+xml">Plasma-Lyte&#174; M and 5% Dextrose Injection
        (Multiple Electrolytes and Dextrose Injection, Type 2, USP)<br />in Viaflex&#174; Plastic
        Container</title>
<effectiveTime value="20060510" />
<setId root="fbf43afb-b192-44bd-89d4-10172fea17a5" />
<versionNumber value="1" />
<author>
<time />
<assignedEntity>
<representedOrganization>
<name>Baxter Healthcare Corporation</name>
</representedOrganization>
</assignedEntity>
</author>
<component>
<structuredBody>
<component>
<section>
<id root="7BA9CBC7-6953-D41E-F08C-82D08AE3034B" />
<effectiveTime value="20060510" />
<subject>
<manufacturedProduct>
<manufacturedMedicine>
<code code="0338-0145" codeSystem="2.16.840.1.113883.6.69" />
<name>Plasma-Lyte M and Dextrose</name>
<formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION" />
<activeIngredient>
<quantity>
<numerator unit="g" value="5">
<translation code="C48155" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="GRAM" value="5" />
</numerator>
<denominator unit="mL" value="100">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="100" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="LX22YL083G" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Dextrose hydrous</name>
<activeMoiety>
<activeMoiety>
<code code="IY9XDZ35W2" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>dextrose</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<activeIngredient>
<quantity>
<numerator unit="mg" value="94">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="94" />
</numerator>
<denominator unit="mL" value="100">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="100" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Sodium Chloride</name>
<activeMoiety>
<activeMoiety>
<code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>sodium chloride</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<activeIngredient>
<quantity>
<numerator unit="mg" value="119">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="119" />
</numerator>
<denominator unit="mL" value="100">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="100" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="660YQ98I10" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Potassium Chloride</name>
<activeMoiety>
<activeMoiety>
<code code="660YQ98I10" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Potassium Chloride</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<activeIngredient>
<quantity>
<numerator unit="mg" value="30">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="30" />
</numerator>
<denominator unit="mL" value="100">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="100" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="02F3473H9O" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Magnesium Chloride</name>
<activeMoiety>
<activeMoiety>
<code code="02F3473H9O" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Magnesium Chloride</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<activeIngredient>
<quantity>
<numerator unit="mg" value="161">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="161" />
</numerator>
<denominator unit="mL" value="100">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="100" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="4550K0SC9B" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Sodium Acetate Trihydrate</name>
<activeMoiety>
<activeMoiety>
<code code="4550K0SC9B" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>sodium acetate</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<activeIngredient>
<quantity>
<numerator unit="mg" value="138">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="138" />
</numerator>
<denominator unit="mL" value="100">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="100" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="TU7HW0W0QT" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Sodium Lactate</name>
<activeMoiety>
<activeMoiety>
<code code="TU7HW0W0QT" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>sodium lactate</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<activeIngredient>
<quantity>
<numerator unit="mg" value="37">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="37" />
</numerator>
<denominator unit="mL" value="100">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="100" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="M4I0D6VV5M" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Calcium Chloride</name>
<activeMoiety>
<activeMoiety>
<code code="M4I0D6VV5M" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Calcium Chloride</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<asEntityWithGeneric>
<genericMedicine>
<name>Sodium chloride, potassium chloride, magnesium chloride, calcium chloride, sodium acetate, sodium lactate and dextrose</name>
</genericMedicine>
</asEntityWithGeneric>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>Water</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Hydrochloric acid</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<asContent>
<quantity>
<numerator unit="mL" value="1000">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="1000" />
</numerator>
<denominator value="1">
<translation codeSystem="2.16.840.1.113883.3.26.1.1" value="1" />
</denominator>
</quantity>
<containerPackagedMedicine>
<code code="0338-0145-04" codeSystem="2.16.840.1.113883.6.69" />
<formCode code="C43167" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BAG" />
</containerPackagedMedicine>
</asContent>
<asContent>
<quantity>
<numerator unit="mL" value="500">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="500" />
</numerator>
<denominator value="1.00">
<translation codeSystem="2.16.840.1.113883.3.26.1.1" value="1.00" />
</denominator>
</quantity>
<containerPackagedMedicine>
<code code="0338-0145-03" codeSystem="2.16.840.1.113883.6.69" />
<formCode code="C43167" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BAG" />
</containerPackagedMedicine>
</asContent>
</manufacturedMedicine>
<consumedIn>
<substanceAdministration>
<routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS" />
</substanceAdministration>
</consumedIn>
</manufacturedProduct>
</subject>
</section>
</component>
<component>
<section ID="INV-950c02a4-16b5-40db-af8d-c9fc087e113c">
<id root="3CEE2DF0-9D8F-3123-B17F-7F864CF4EFF5" />
<code code="34089-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="DESCRIPTION SECTION" />
<title ID="INV-49ea1bf9-70c7-4872-8c23-be1807ae5fdc" mediaType="text/x-hl7-title+xml">DESCRIPTION</title>
<text ID="INV-a00504b3-8121-433c-8a19-709d454132d5"><paragraph ID="INV-c1f13f13-b1a0-4237-9e44-cb4bdaac45fb">Plasma-Lyte&#174; M and
                            5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection,
                            Type 2, USP) is a sterile, nonpyrogenic solution for fluid and
                            electrolyte replenishment and caloric supply in a single dose container
                            for intravenous administration. Each 100 mL contains 5 g Dextrose
                            Hydrous, USP*, 161 mg Sodium Acetate Trihydrate, USP
                                (C<sub>2</sub>H<sub>3</sub>NaO<sub>2</sub>&#8226;3H<sub>2</sub>O); 138 mg
                            Sodium Lactate (C<sub>3</sub>H<sub>5</sub>NaO<sub>3</sub>), 119 mg
                            Potassium Chloride, USP (KCl), 94 mg Sodium Chloride, USP (NaCl), 37 mg
                            Calcium Chloride, USP (CaCl<sub>2</sub>&#8226;2H<sub>2</sub>O), and 30 mg
                            Magnesium Chloride, USP (MgCl<sub>2</sub>&#8226;6H<sub>2</sub>O). It contains
                            no antimicrobial agents. The pH is 5.0 (4.0 to 6.5). The pH is adjusted
                            with hydrochloric acid.</paragraph><renderMultiMedia referencedObject="MM-ff2086ca-04cd-4848-909c-8a6284918194" /><paragraph ID="INV-4d068814-07e5-4fe9-a946-cd177c618592">Plasma-Lyte&#174; M and
                            5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection,
                            Type 2, USP) administered intravenously has value as a source of water,
                            electrolytes, and calories. One liter has an ionic concentration of 40
                            mEq sodium, 16 mEq potassium, 5 mEq calcium, 3 mEq magnesium, 40 mEq
                            chloride, 12 mEq acetate, and 12 mEq lactate. The osmolarity is 377
                            mOsmol/L (calc). Normal physiologic osmolarity range is approximately
                            280 to 310 mOsmol/L. Administration of substantially hypertonic
                            solutions (&#8805; 600 mOsmol/L) may cause vein damage. The caloric content is
                            180 kcal/L. </paragraph><paragraph ID="INV-a6216aba-1740-4200-b6f3-445447c87009">The Viaflex&#174;
                            plastic container is fabricated from a specially formulated polyvinyl
                            chloride (PL 146&#174; Plastic). The amount of water that can permeate from
                            inside the container into the overwrap is insufficient to affect the                       solution significantly. Solutions in contact with the plastic container
                            may leach out certain chemical components from the plastic in very small
                            amounts; however, biological testing was supportive of the safety of the
                            plastic container materials.</paragraph></text>
<effectiveTime value="20060510" />
<component>
<observationMedia ID="MM-ff2086ca-04cd-4848-909c-8a6284918194">
<value mediaType="image/jpeg"><reference value="Plasma-017390.jpg" /></value>
</observationMedia>
</component>
</section>
</component>
<component>
<section ID="INV-ef312cbc-d491-4a04-937a-ae9e09b4293e">
<id root="63B4DCD8-949F-F336-3E4D-17B0C2B682DE" />
<code code="34090-1" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="CLINICAL PHARMACOLOGY SECTION" />
<title ID="INV-eb0e5e9d-c7f9-41a9-a001-a99bb72d15db" mediaType="text/x-hl7-title+xml">CLINICAL PHARMACOLOGY</title>
<text ID="INV-efc0a013-dc7a-46d9-8ca2-c5df8e8b1e35"><paragraph ID="INV-29e6347a-90d0-4092-9b52-ca9c797ea01b">Plasma-Lyte&#174; M and
                            5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection,
                            Type 2, USP) has value as a source of water, electrolytes, and calories.
                            It is capable of inducing diuresis depending on the clinical condition
                            of the patient. </paragraph><paragraph ID="INV-33265554-1303-44ab-84d4-8a1b7580b327">Plasma-Lyte&#174; M and    5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection,
                            Type 2, USP) produces a metabolic alkalinizing effect. Acetate and
                            lactate ions are metabolized ultimately to carbon dioxide and water,
                            which requires the consumption of hydrogen cations.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section ID="INV-381c0a92-76a2-4cc6-bfde-272716db1d5c">
<id root="9D589CD6-417B-B6D5-3F6F-BD69E4C99B51" />
<code code="34067-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="INDICATIONS AND USAGE SECTION" />
<title ID="INV-5fe1a603-9a7b-413a-8f66-0bda02828c78" mediaType="text/x-hl7-title+xml">INDICATIONS AND USAGE</title>
<text ID="INV-c02698c6-dfac-4f96-9278-7bad9b1cb6cc"><paragraph ID="INV-7ee88896-bee2-405b-b1a6-e1d8c22c0237">Plasma-Lyte&#174; M and
                            5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection,
                            Type 2, USP) is indicated as a source of water, electrolytes, and
                            calories or as an alkalinizing agent.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section ID="INV-575d0e41-a77c-4625-929d-4b73d7c2de0c">
<id root="2E8460F2-91B4-DE43-2221-20085C09A6D3" />
<code code="34070-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="CONTRAINDICATIONS SECTION" />
<title ID="INV-d77daa05-de5a-4044-8ac6-a9c8d5cce7bf" mediaType="text/x-hl7-title+xml">CONTRAINDICATIONS</title>
<text ID="INV-8b9c1c39-8e7b-4193-b0fe-ab5b78f4716b"><paragraph ID="INV-1996d959-5470-4b45-85a5-503daeed5a73">Solutions containing dextrose may be contraindicated in patients with known
                            allergy to corn or corn products.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section ID="INV-0e4d4865-7347-4aa8-8a51-15be2a51f6d7">
<id root="99EBF4A4-77C8-9108-149F-0BEF09AD9160" />
<code code="34071-1" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="WARNINGS SECTION" />
<title ID="INV-7480358c-5148-4a3a-829b-d6663ae438e4" mediaType="text/x-hl7-title+xml">WARNINGS</title>
<text ID="INV-7475d5fe-917d-4060-a866-00f81d1695df"><paragraph ID="INV-de0dd79a-60e3-43c8-ab66-b0fbc34bc54d">Plasma-Lyte&#174; M and
                            5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection,
                            Type 2, USP) should be used with great care, if at all, in patients with
                            congestive heart failure, severe renal insufficiency, and in clinical
                            states in which there exists edema with sodium retention. </paragraph><paragraph ID="INV-0f865770-14e8-4e02-9a1a-36b86ab88fc4">Plasma-Lyte&#174; M and
                            5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection,
                            Type 2, USP) should be used with great care, if at all, in patients with
                            hyperkalemia, severe renal failure, and in conditions in which potassium
                            retention is present. </paragraph><paragraph ID="INV-726c80f2-8a6b-4105-bc99-7e3f1702e0a5">Plasma-Lyte&#174; M and
                            5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection,
                            Type 2, USP) should be used with great care in patients with metabolic
                            or respiratory alkalosis. The administration of lactate or acetate ions
                            should be done with great care in those conditions in which there is an
                            increased level or an impaired utilization of these ions, such as severe
                            hepatic insufficiency. </paragraph><paragraph ID="INV-609a49d1-9ba7-4a76-b3a0-9e89b76deb1c">Plasma-Lyte&#174; M and
                            5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection,
                            Type 2, USP) should not be administered simultaneously with blood
                            through the same administration set because of the likelihood of
                            coagulation. </paragraph><paragraph ID="INV-312102f5-ad23-4526-b2a8-4632da5c2f62">The intravenous
                            administration of Plasma-Lyte&#174; M and 5% Dextrose Injection (Multiple
                            Electrolytes and Dextrose Injection, Type 2, USP) can cause fluid and/or
                            solute overloading resulting in dilution of serum electrolyte
                            concentrations, overhydration, congested states, or pulmonary edema. The
                            risk of dilutional states is inversely proportional to the electrolyte
                            concentrations of the injection. The risk of solute overload causing            congested states with peripheral and pulmonary edema is directly
                            proportional to the electrolyte concentrations of the injection. </paragraph><paragraph ID="INV-4a97bbe6-bfb3-46f6-8321-f3d1e206a94d">In patients with
                            diminished renal function, administration of Plasma-Lyte&#174; M and 5%
                            Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type
                            2, USP) containing sodium or potassium ions may result in sodium or                potassium retention. </paragraph><paragraph ID="INV-2a59c7d7-350b-4ae4-b007-4a846350f6eb">Plasma-Lyte&#174; M and
                            5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection,
                            Type 2, USP) is not for use in the treatment of lactic
                        acidosis.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section ID="INV-9b340506-11f5-4506-a334-71e2fe390c5d">
<id root="175ADB5E-40C2-D6CB-796D-61E0069C80BB" />
<code code="34072-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="GENERAL PRECAUTIONS SECTION" />
<title ID="INV-a99a8998-ce75-4ebd-b424-eb5a2ad371ee" mediaType="text/x-hl7-title+xml">GENERAL PRECAUTIONS</title>
<text ID="INV-f8894684-d070-481e-b248-5dc27aab4ba0"><paragraph ID="INV-2de8d514-382d-4cfe-ad58-587314c56e91">Clinical evaluation
                            and periodic laboratory determinations are necessary to monitor changes
                            in fluid balance, electrolyte concentrations, and acid base balance
                            during prolonged parenteral therapy or whenever the condition of the
                            patient warrants such evaluation. </paragraph><paragraph ID="INV-aec36a39-f614-488d-8009-d7f82917524d">Plasma-Lyte&#174; M and                         5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection,
                            Type 2, USP) should be used with caution. Excess administration may
                            result in metabolic alkalosis. </paragraph><paragraph ID="INV-9e9d8d76-239d-4f8b-9019-3559ef60b7b4">Caution must be
                            exercised in the administration of Plasma-Lyte&#174; M and 5% Dextrose
                            Injection (Multiple Electrolytes and Dextrose Injection, Type 2, USP) to
                            patients receiving corticosteroids or corticotropin. </paragraph><paragraph ID="INV-46a6a3a3-8e3c-40bf-a6aa-bc7614a97d81">Plasma-Lyte&#174; M and
                            5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection,
                            Type 2, USP) should be used with caution in patients with overt or
                            subclinical diabetes mellitus.</paragraph></text>
<effectiveTime value="20060510" />
<component>
<section ID="INV-800c3348-0b78-451f-b348-26d0f7902ce3">
<id root="DB5F07F8-9D77-240C-403C-94365C6C5AC6" />
<code code="42228-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="PREGNANCY" />
<title ID="INV-c2758023-931e-4fb6-b0d2-760ce645dea9" mediaType="text/x-hl7-title+xml">Pregnancy</title>
<effectiveTime value="20060510" />
<component>
<section ID="INV-ebfc130a-4f75-4ce4-946b-b0bc4b9c12be">
<id root="B26CDE0E-15EA-B4B3-1178-DCA540B68CF0" />
<code code="34077-8" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="TERATOGENIC EFFECTS SECTION" />
<title ID="INV-986de999-46d4-41e1-905b-517eb69e4d53" mediaType="text/x-hl7-title+xml">Teratogenic
                                        Effects</title>
<effectiveTime value="20060510" />
<component>
<section>
<id root="2CE5687F-5540-4DB9-756E-53AC26021151" />
<title ID="INV-b8ebedb8-e95a-47ad-a5ee-38ef1bae6bf2" mediaType="text/x-hl7-title+xml">Pregnancy Category C</title>
<text ID="INV-1abcb11e-d921-4c43-97eb-66cb9a34219c"><paragraph ID="INV-1c73eb6c-30d8-4a50-9fe6-6de06f615972">Animal reproduction studies have not been
                                                  conducted with Plasma-Lyte&#174; M and 5% Dextrose
                                                  Injection (Multiple Electrolytes and Dextrose
                                                  Injection, Type 2, USP). It is also not known
                                                  whether Plasma-Lyte&#174; M and 5% Dextrose Injection
                                                  (Multiple Electrolytes and Dextrose Injection,
                                                  Type 2, USP) can cause fetal harm when
                                                  administered to a pregnant woman or can affect
                                                  reproduction capacity. Plasma-Lyte&#174; M and 5%
                                                  Dextrose Injection (Multiple Electrolytes and
                                                  Dextrose Injection, Type 2, USP) should be given
                                                  to a pregnant woman only if clearly
                                                needed.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
</section>
</component>
</section>
</component>
<component>
<section ID="INV-1628f512-0755-4245-a99b-cc332e884c28">
<id root="0AFA6EDA-F3E7-A348-00D9-EFC1480D68AE" />
<code code="34081-0" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="PEDIATRIC USE SECTION" />
<title ID="INV-4f917ae7-7696-4f68-9653-72925e5383f4" mediaType="text/x-hl7-title+xml">Pediatric Use</title>
<text ID="INV-0114669f-3366-45ae-ad2f-9793454ae568"><paragraph ID="INV-6256a749-758a-4574-b8b1-00bfdecd1ea0">Safety and
                                    effectiveness of Plasma-Lyte&#174; M and 5% Dextrose Injection
                                    (Multiple Electrolytes and Dextrose Injection, Type 2, USP) in
                                    pediatric patients have not been established by adequate and
                                    well controlled trials, however, the use of plasmalyte and
                                    dextrose solutions in the pediatric population is referenced in
                                    the medical literature. The warnings, precautions and adverse
                                    reactions identified in the label copy should be observed in the
                                    pediatric population. </paragraph><paragraph ID="INV-c939618d-8e16-4569-a26a-b875ce9dba01">In very low
                                    birth weight infants, excessive or rapid administration of
                                    dextrose injection may result in increased serum osmolality and
                                    possible hemorrhage.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section ID="INV-e41a6ece-fe62-45a0-ac10-158e42106eec">
<id root="E00F30DD-915C-95DB-A0B4-A8B4A63432A7" />
<code code="34083-6" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="CARCINOGENESIS AND MUTAGENESIS AND IMPAIRMENT OF FERTILITY SECTION" />
<title ID="INV-94f8829f-555c-49e4-9265-6f24490a85a0" mediaType="text/x-hl7-title+xml">Carcinogenesis and
                                Mutagenesis and Impairment of Fertility</title>
<text ID="INV-0529c66a-91a7-4772-9888-962cbae3e868"><paragraph ID="INV-9e96a10f-6a01-468f-ac64-3838b838e579">Studies
                                    with Plasma-Lyte&#174; M and 5% Dextrose Injection (Multiple                                    Electrolytes and Dextrose Injection, Type 2, USP) have not been
                                    performed to evaluate carcinogenic potential, mutagenic
                                    potential, or effects on fertility.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section ID="INV-ad9d2e53-ae72-4d33-be04-4451c0a0e0b9">
<id root="2533DC2D-C89D-9991-B303-54CE4CFE1BC4" />
<code code="34080-2" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="NURSING MOTHERS SECTION" />
<title ID="INV-cf3b2acb-a0ce-41e2-9026-a7082fe43d87" mediaType="text/x-hl7-title+xml">Nursing Mothers</title>
<text ID="INV-dbd07925-3acd-4567-92a7-0c43f43f837f"><paragraph ID="INV-5647eae6-c436-4f07-908c-4207f65cf586">It is not
                                    known whether this drug is excreted in human milk. Because many
                                    drugs are excreted in human milk, caution should be exercised
                                    when Plasma-Lyte&#174; M and 5% Dextrose Injection (Multiple
                                    Electrolytes and Dextrose Injection, Type 2, USP) is
                                    administered to a nursing mother.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section ID="INV-12c260c3-361e-45aa-bd79-8a2ee5cf838f">
<id root="B83C12EA-BBFF-B043-1BB9-06BDF0AA8B64" />
<code code="34082-8" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="GERIATRIC USE SECTION" />
<title ID="INV-f734aaa9-b188-473e-888b-1981528a4197" mediaType="text/x-hl7-title+xml">Geriatric Use</title>
<text ID="INV-ffe3cbb9-8c1b-4a74-9221-f32e1c0af743"><paragraph ID="INV-4e50d98a-a157-49e9-a0d2-07ee7e5da3fa">Clinical
                                    studies of Plasma-Lyte&#174; M and 5% Dextrose Injection (Multiple
                                    Electrolytes and Dextrose Injection, Type 2, USP) did not
                                    include sufficient numbers of subjects aged 65 and over to
                                    determine whether they respond differently from younger
                                    subjects. Other reported clinical experience has not identified
                                    differences in responses between the elderly and younger
                                    patients. In general, dose selection for an elderly patient
                                    should be cautious, usually starting at the low end of the
                                    dosing range, reflecting the greater frequency of decreased
                                    hepatic, renal, or cardiac function, and of concomitant disease
                                    or drug therapy.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
</section>
</component>
<component>
<section ID="INV-94e05a88-0640-4406-9307-e7c54f6724b7">
<id root="8FE6DC69-C1BF-F1AB-230D-B01F4309CD44" />
<code code="34084-4" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="ADVERSE REACTIONS SECTION" />
<title ID="INV-b5ad35ca-5bcd-40d2-be27-0484e15f54ff" mediaType="text/x-hl7-title+xml">ADVERSE REACTIONS</title>
<text ID="INV-56d5408e-1a16-4413-b46d-94310082ad58"><paragraph ID="INV-53d91fd9-6aee-4f39-baa8-a22028f3c800">Reactions which may
                            occur because of the solution or the technique of administration include
                            febrile response, infection at the site of injection, venous thrombosis
                            or phlebitis extending from the site of injection, extravasation, and
                            hypervolemia. </paragraph><paragraph ID="INV-54df216d-f866-4021-befb-c95a53e551a9">If an adverse
                            reaction does occur, discontinue the infusion, evaluate the patient,
                            institute appropriate therapeutic countermeasures, and save the
                            remainder of the fluid for examination if deemed necessary.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section ID="INV-d0bf4725-e736-42a7-a47a-4abe3cc624b4">
<id root="72E0D785-374D-8A31-DDA8-8D7C3DE907C9" />
<code code="34068-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="DOSAGE AND ADMINISTRATION SECTION" />
<title ID="INV-467de4b9-e487-4b78-9e58-8ea60b8ad268" mediaType="text/x-hl7-title+xml">DOSAGE AND ADMINISTRATION</title>
<text ID="INV-94ca8746-573d-4558-8f57-31cf0d1d57d1"><paragraph ID="INV-eff443d7-833f-4fca-9583-f69cf0708adb">As directed by a
                            physician. Dosage is dependent upon the age, weight and clinical
                            condition of the patient as well as laboratory determinations. </paragraph><paragraph ID="INV-b41e6739-e8a5-4c3b-b1d2-98e3a1ff5e9a">Parenteral drug
                            products should be inspected visually for particulate matter and
                            discoloration prior to administration whenever solution and container
                            permit. </paragraph><paragraph ID="INV-60b94ed4-cca4-4eea-889c-e19f4456860f">All injections in
                            Viaflex&#174; plastic containers are intended for intravenous administration
                            using sterile equipment. </paragraph><paragraph ID="INV-7ecd43ed-1aa4-4c77-bda6-ceed5c3d3e5e">As reported in the
                            literature, the dosage and constant infusion rate of intravenous
                            dextrose must be selected with caution in pediatric patients,
                            particularly neonates and low weight infants, because of the increased
                            risk of hyperglycemia/hypoglycemia. </paragraph><paragraph ID="INV-c51e4596-822e-485d-a6f7-6e6dc1b3b509">Additives may be
                            incompatible. Complete information is not available. Those additives
                            known to be incompatible should not be used. Consult with pharmacist, if
                            available. If, in the informed judgment of the physician, it is deemed
                            advisable to introduce additives, use aseptic technique. Mix thoroughly
                            when additives have been introduced. Do not store solutions containing
                            additives.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section ID="INV-9045f47a-f5e2-48fb-a1b7-a0f816746ee5">
<id root="CDC44895-7A99-010E-EE08-B8A5DF34C29F" />
<code code="34069-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="HOW SUPPLIED SECTION" />
<title ID="INV-2eb2c955-125e-4bef-a4b6-d2ef879aba62" mediaType="text/x-hl7-title+xml">HOW SUPPLIED</title>
<text ID="INV-16f12839-978a-4701-89f9-2b15fc40be9c"><paragraph ID="INV-43742a89-310f-4958-b193-7743badbcc61">Plasma-Lyte&#174; M and
                            5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection,
                            Type 2, USP) in Viaflex&#174; plastic containers is available as shown below:</paragraph><table frame="void"><col align="left" width="147.75pt" />
<col align="left" width="147.75pt" />
<col align="left" width="147.75pt" />
<tbody valign="top">
<tr valign="top"><td align="center" valign="top">Size (mL)</td><td align="center" valign="top">Code</td><td align="center" valign="top">NDC</td></tr>
<tr valign="top"><td align="center" valign="middle">1000</td><td align="center" valign="middle">2B2564</td><td align="center" valign="middle">NDC 0338-0145-04</td></tr>
<tr valign="top"><td align="center" valign="middle">500</td><td align="center" valign="middle">2B2563</td><td align="center" valign="middle">NDC 0338-0145-03</td></tr>
</tbody>
</table><paragraph ID="INV-c3e02143-3047-4be7-939a-de973c1dcfb7">Exposure of
                            pharmaceutical products to heat should be minimized. Avoid excessive
                            heat. It is recommended the product be stored at room temperature
                            (25&#176;C); brief exposure up to 40&#176;C does not adversely affect the
                        product.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section ID="INV-7cf524e1-24cc-43a0-a34b-d7d4576a66e7">
<id root="55B006BA-0FDF-A173-1F4A-2E6108109B46" />
<title ID="INV-17b21fc0-1d6d-4023-875b-c5ea7190a309" mediaType="text/x-hl7-title+xml">DIRECTIONS FOR USE OF
                        VIAFLEX&#174; PLASTIC CONTAINER </title>
<effectiveTime value="20060510" />
<component>
<section ID="INV-32ad12e0-e59b-45ea-bd67-e0f9959e471f">
<id root="D1387453-1BD7-F4AD-64BB-FEF1E6B49E61" />
<title ID="INV-382f2619-6142-4304-aaa8-ad103c57807d" mediaType="text/x-hl7-title+xml">Warning:</title>
<text ID="INV-9933049e-28d2-4a9e-b5e4-02d7d47f1428"><paragraph ID="INV-0d9bbb89-f54d-44ab-9266-2b4f7a25eac2">Do not use
                                    plastic containers in series connections. Such use could result
                                    in air embolism due to residual air being drawn from the primary
                                    container before administration of the fluid from the secondary
                                    container is completed.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section ID="INV-787b4ef0-a7d5-4b15-9394-bbf696624b1e">
<id root="93EB0670-7C2F-D442-D247-BEFF409431F1" />
<title ID="INV-522ae348-93fd-4914-b519-b37082f3d26e" mediaType="text/x-hl7-title+xml">To Open</title>
<text ID="INV-4860bab0-eb88-452e-86e7-24633aed6f4e"><paragraph ID="INV-d161e65c-57aa-4335-bc59-2f1e84376d26">Tear
                                    overwrap down side at slit and remove solution container. Some
                                    opacity of the plastic due to moisture absorption during the                               sterilization process may be observed. This is normal and does
                                    not affect the solution quality or safety. The opacity will
                                    diminish gradually. Check for minute leaks by squeezing inner
                                    bag firmly. If leaks are found, discard solution as sterility
                                    may be impaired. If supplemental medication is desired, follow
                                    directions below.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section ID="INV-f9b808e3-9528-43c1-bab1-1a6788d1eabe">
<id root="55DC27D5-8B38-E2B0-A379-CF4B2BACE939" />
<title ID="INV-9bcc0637-bea3-4afb-bb98-64267a0ae31d" mediaType="text/x-hl7-title+xml">Preparation for
                                Administration</title>
<text ID="INV-cb033fe7-d4a5-4c74-a3f1-8cd5734a1892"><paragraph ID="INV-5fd47a94-40bf-442b-80af-a8e568ca189c">1. Suspend
                                    container from eyelet support. </paragraph><paragraph ID="INV-c07ac242-f525-48d8-9b01-492172f9a03f">2. Remove
                                    plastic protector from outlet port at bottom of container. </paragraph><paragraph ID="INV-acb8d1fe-ed37-457e-952d-d3cae9438488">3. Attach
                                    administration set. Refer to complete directions accompanying
                                    set.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section ID="INV-01c43509-b778-4bac-a5a4-227975541ee5">
<id root="B2D3FABF-AC31-A507-7119-1F07B9C28EC3" />
<title ID="INV-09038359-08b2-4ac1-9bea-96d0ed743560" mediaType="text/x-hl7-title+xml">To Add
                            Medication</title>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section ID="INV-8b225fcb-06b0-47c8-85f0-55e4da953b0e">
<id root="20A43C76-A901-F8B5-5005-4F03AD05CE8F" />
<title ID="INV-33288739-c11b-47eb-8bdd-f625399322b6" mediaType="text/x-hl7-title+xml">Warning:</title>
<text ID="INV-f8af9d5b-c314-46f0-9d5c-55da0e272898"><paragraph ID="INV-d88b1fbb-7bbc-4f7e-9c06-b42f61fb4770">Additives
                                    may be incompatible.</paragraph></text>
<effectiveTime value="20060510" />
<component>
<section ID="INV-533d66dc-f9cd-4748-8ef8-a878b6d6d326">
<id root="3225D531-E8A3-81ED-EBD1-3A9046DD5C10" />
<title ID="INV-8ce2b1e0-6b09-4891-9078-12eb4ec9bfc5" mediaType="text/x-hl7-title+xml">To add
                                        medication before solution administration</title>
<text ID="INV-51c6f995-7548-4852-8b38-2c80af7b7b1a"><paragraph ID="INV-462a3437-dc77-4a7a-817c-535cb66d2888">1.
                                            Prepare medication site. </paragraph><paragraph ID="INV-0fc348b0-fb18-40ba-a0f9-31bd03f80f04">2.
                                            Using syringe with 19 to 22 gauge needle, puncture                      resealable medication port and inject. </paragraph><paragraph ID="INV-01c52cbe-6ea2-444f-9cf6-d173bf83a909">3.
                                            Mix solution and medication thoroughly. For high density
                                            medication such as potassium chloride, squeeze ports
                                            while ports are upright and mix thoroughly. </paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section ID="INV-00fa8e12-9d40-47de-a9b5-eda24af71d34">
<id root="129F5693-27D0-BD00-9504-1476E211C017" />
<title ID="INV-4b39fdff-846b-4969-aa4e-e5cdcf01fd45" mediaType="text/x-hl7-title+xml">To add
                                        medication during solution administration</title>
<text ID="INV-57a678ee-2655-437b-8a7f-2ed0e2d77eed"><paragraph ID="INV-1d91f634-af53-4aa7-85ac-ef53fb012496">1.
                                            Close clamp on the set. </paragraph><paragraph ID="INV-a450120e-e2b1-4029-8855-f529df0a9323">2.
                                            Prepare medication site. </paragraph><paragraph ID="INV-9a3ae150-987d-4e61-bd5a-dacbb4137830">3.
                                            Using syringe with 19 to 22 gauge needle, puncture
                                            resealable medication port and inject. </paragraph><paragraph ID="INV-8b0999b8-0d23-46a0-a878-f62a042522ad">4.
                                            Remove container from IV pole and/or turn to an upright
                                            position. </paragraph><paragraph ID="INV-8daeb8c9-aa1e-4208-8f6c-d4c166f05059">5.
                                            Evacuate both ports by squeezing them while container is
                                            in the upright position.</paragraph><paragraph ID="INV-0b5e00f2-cd48-4a0c-8cd5-805d19097960">6.
                                            Mix solution and medication thoroughly. </paragraph><paragraph ID="INV-7e0b28b7-2c2c-47af-a3b1-d0bc320f8992">7.
                                            Return container to in use position and continue
                                            administration.</paragraph><paragraph ID="INV-747b3649-ef0a-41df-b910-f12fda92d10a"><content styleCode="bold">Baxter Healthcare
                                            Corporation</content></paragraph><paragraph ID="INV-a20322ed-4726-4509-97e7-690f9b4ccf42">Deerfield, IL 60015 USA </paragraph><paragraph ID="INV-b8c84d97-81a2-488f-b4d8-1079e9420cc8">Printed in USA</paragraph><paragraph ID="INV-8c4732bb-9af1-40aa-8ee3-a3b8e9fe2b11">&#169;Copyright 1982, 1983, 1984, 1989, 1993, Baxter
                                            Healthcare Corporation. </paragraph><paragraph ID="INV-998c4f13-3f50-45f8-ac66-8347acebe4ad">All
                                            rights reserved. </paragraph><paragraph ID="INV-3f168b2a-f748-43f5-a59d-40073c11f42a"><content styleCode="bold">7-19-22-967</content></paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
</section>
</component>
</section>
</component>
</structuredBody>
</component>
</document>
